|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To evaluate the role of constitutive epigenetic changes in normal body cells of BRCA1/BRCA2-mutation negative patients, we have developed a deep bisulfite sequencing assay targeting the promoter regions of 8 tumor suppressor (TS) genes (BRCA1, BRCA2, RAD51C, ATM, PTEN, TP53, MLH1, RB1) and the estrogene receptor gene (ESR1), which plays a role in tumor progression.
|
29659014 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Five PDX models were evaluated in vivo.Tumor regressions were induced by single-agent niraparib in one of two PDX models with deleterious BRCA2 mutations and in a PDX with RAD51C promoter methylation.
|
27614696 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cytoplasmic expression (RAD51C(+)) and lack of nuclear expression (RAD51 N(-)) were associated with features of aggressive behaviour, including larger tumour size, high grade, lymph nodal metastasis, basal-like, and triple-negative phenotypes, together with aberrant expression of key DDR biomarkers including BRCA1.
|
27464795 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We have also found an association of a worse clinical outcome between RAD51C expression and ERα status of tumors.
|
27753535 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Nonetheless, loss of Rad51c shortens the latency of Trp53-deficient mouse tumors from 11 to 6 months.
|
26820992 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of Rad51C variants is associated with FANCD2 foci positive colorectal tumors and is associated with microsatellite stability in those tumors.
|
25669972 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, olaparib significantly suppressed RAD51C-deficient tumor growth in a xenograft model.
|
23512992 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, these results unravel the critical role of RAD51C in the FA pathway of ICL repair and as a tumor suppressor.
|
22167183 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we focus on describing the functions of RAD51C in HR, DNA damage signaling and as a tumor suppressor with an emphasis on the new roles of RAD51C unveiled by these reports.
|
20952512 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression analysis in 12 primary tumors showed that RAD51C and S6K were consistently expressed in all cases in which they were amplified and also in some tumors without amplification.
|
11034067 |
2000 |